Agios Pharmaceuticals, Inc. (AGIO) Stock Grade

About Agios Pharmaceuticals, Inc.'s fundamentals

Agios Pharmaceuticals is a biotechnology company with a market capitalization of $1.6 billion that demonstrated strong revenue growth of 48.0% year-over-year, indicating expanding commercial operations. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -764.0%, meaning expenses substantially exceed revenue. As a development-stage biotech firm, the company does not pay a dividend and traditional valuation metrics like P/E ratio and return on equity are not meaningful due to its loss-making status.